FDA Blackballs Sun Pharma Plant In Import Safety Crackdown

Law360, New York (March 13, 2014, 4:00 PM EDT) -- The U.S. Food and Drug Administration on Wednesday continued a parade of enforcement actions targeting Indian drugmakers’ quality control, blocking imports from a Sun Pharmaceutical Industries Ltd. plant found to be noncompliant with U.S. safe-manufacturing standards.

The Mumbai-based generic drug manufacturer’s Karkhadi facility, in the state of Gujarat on India’s northwest coast, was placed on import alert for unspecified violations of current good-manufacturing standards, compelling U.S. customs agents to seize shipments originating there until the FDA says otherwise. The plant makes cephalosporins, a class of powerful...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.